Israel Secondary Fund (ISF)

Israel Secondary Fund ("ISF") acquires interests in Israel related funds and private companies from investors, founders and employees. Since the inception of the secondary market in Israel in 1998, ISF's partners have played a major role in it, executing dozens of transactions. Our investment professionals have experience in a broad range of secondary transactions as well as hands on experience as partners in venture capital and private equity firms. We have collaborated with the majority of PE and VC funds active in Israel, international & Israeli institutions and have formed close relationships with employees, founders and managers of companies. We believe in the value ISF brings to stakeholders in the Venture Capital and Private Equity community. Creative, discrete and straightforward with a view for long term partnerships and growth, is our way of doing business. What We do: Limited Partners Positions - ISF acquires Limited Partners interests in Israel related VC & PE funds with diversified portfolios. We tailor the transaction to suit the requirements of the sellers and assume future capital commitments. Secondary Direct - ISF acquires interests in Israel-related private companies and portfolios. Sellers include funds, investors, founders and employees. When needed we create Special Purpose Vehicles together with existing GPs or Managers. Structured Secondaries - ISF provides customized solutions, to provide additional capital to Funds and to Limited Partners seeking to reduce risk. When needed we work with fund management and LPs to construct annex funds or other special vehicles.

Shmuel Shilo

Founding Partner

4 past transactions

V-Wave

Series C in 2021
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

V-Wave

Series C in 2020
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.

Eyeview

Venture Round in 2018
Eyeview Inc. is a video advertising technology company based in New York that specializes in providing brands with effective return on investment for their video advertising expenditures. The company’s flagship platform, VideoIQ, integrates consumer, brand, and retail data to create personalized, one-to-one video advertisements, which can be delivered programmatically across various platforms, including television, desktop, tablet, and mobile devices. Eyeview also offers a range of solutions tailored to specific industries, such as lead generation for the automotive sector, in-store marketing for consumer packaged goods, and online booking for travel. The platform can be utilized through a managed service with support from Eyeview's team or via a self-service interface. Established in 2007, Eyeview has garnered recognition for its rapid growth and serves notable clients such as P&G, Walgreens, Lowes, Honda, and BMW.

V-Wave

Series C in 2018
V-Wave Ltd. is a private company that develops percutaneous implantable therapeutic devices for patients suffering from chronic heart failure. Founded in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave has created a proprietary interatrial shunt designed to alleviate symptoms associated with both preserved and reduced ejection fraction heart failure. This biocompatible implant regulates left atrial pressure, addressing a key factor in the deterioration of heart failure. The device aims to enhance patients' quality of life by reducing hospitalizations and improving exercise capacity. V-Wave's team consists of experienced engineers and medical scientists dedicated to advancing treatment options for individuals who continue to experience debilitating symptoms despite optimal medical care.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.